Ozagrel

CHEMBL11662 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

228.2 g/mol

LogP

1.6

Phase

4

A thromboxane synthase inhibitor used in Japan to treat ischemic stroke and prevent thrombosis by reducing production of thromboxane A2, a potent promoter of platelet aggregation and vasoconstriction. It helps restore blood flow and prevents further clot formation in affected blood vessels.

分子量

228.2500 g/mol

LogP

1.60

TPSA

55.10 Å²

Lipinski 五规则

符合

Pharmacokinetics (PK)

Pharmacodynamics (PD)

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)/C=C/c1ccc(Cn2ccnc2)cc1

InChI

InChI=1S/C13H12N2O2/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15/h1-8,10H,9H2,(H,16,17)/b6-5+

Molecular Formula

C13H12N2O2

HBD / HBA

1 / 3

可旋转键数

4

重原子数

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A thromboxane synthase inhibitor used in Japan to treat ischemic stroke and prevent thrombosis by reducing production of thromboxane A2, a potent promoter of platelet aggregation and vasoconstriction. It helps restore blood flow and prevents further clot formation in affected blood vessels.

Yes, Ozagrel is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL11662. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5282440. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

正在寻找患者友好型信息？

Ozagrel 在 PillFYI 上

结构

快速数据

分子式: C13H12N2O2

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.